Chlamydia infection Trends in diagnostic and therapeutic markets and business strategies

Chlamydia is a common sexually transmitted infection caused by the bacterium Chlamydia trachomatis. Chlamydia is one of the most prevalent sexually transmitted diseases (STDs) and, according to the Centers for Disease Control and Prevention (CDC), is the largest proportion of all STDs registered in the United States since 1994.

In 2012 , Chlamydia infection were reported to CDC in 50 states and the District of Columbia. In general, the case rate among men in 2012 increased by 3.2% during 2011-2012, which is approximately half the rate of reported cases in women. Chlamydia infection among women is generally asymptomatic. However, if left untreated, it can become pelvic inflammatory disease (PID), which is a major cause of infertility, ectopic pregnancy and chronic pelvic pain.

Like other STDs, chlamydia infection could facilitate the transmission of human immunodeficiency virus (HIV) infection. On the other hand, pregnant women infected with chlamydia can transmit the infection to their babies during childbirth, which could lead to neonatal ophthalmia and pneumonia. In Europe there are more than 250,000 new cases reported each year and women under 24 in Europe have the highest number of infections. In 2012, the National Health Service, U.K., 206,912 people underwent chlamydia testing in England, of which 64% were under 25 years of age.

Among women, the symptoms of chlamydia include abnormal vaginal discharge, painful periods, and abdominal pain with fever. In addition to itching and burning around the vagina and mild pain during urination. While among the symptoms of men like cloudy flow, painful urination, burning around the genital area and swelling of the testicles are commonly found.

Drugs commonly used to treat chlamydia include Amoxil, Doryx, Doxycycline, Erythrocin, Floxin, Gantrisin, Trimox, Zithromax and others. Some emerging diagnostic techniques in the global Chlamydia and Therapeutics Infection Diagnostics market include molecular diagnostics, immunoassays, monoclonal antibodies, flow cytometry, and gel-based moicrodroplet tests. Leading drivers for market growth include the growing collaborative agreement with distributors, manufacturers and universities related to manufacturing and research activities have escalated the market in recent years. Drugs pipelined on the market include CEL-1000, Cyanovirin-N, GEN-001, acALY18 and others.

Geographically, the chlamydia market is prevalent in developed regions such as the United States and Europe. Key factors contributing to the growth of these markets include the intensive funding of research and government interventions for the development of affordable and affordable drugs for sexually transmitted diseases under the Affordable CARE Act. The availability of advanced diagnostic centers, clinics and hospitals has also contributed to the growth and development of the market in the last ten years.

Asia Pacific and the rest of the global market is potentially a lucrative market and has the fastest growth rate compared to other regions related to the increase in sexually transmitted diseases incidences and lack of diagnostics and appropriate care centers for diseases. Approximately 43 million new cases of chlamydia are reported in the Southeast Asian region. Considering that, according to the World Health Organization 1999, the prevalence rate of chlamydia in the Western Pacific region ranges from 5.7% in Thailand to 17% in India. The above data clearly represent the latent growth potential for the pharmaceutical and diagnostic companies that manufacture chlamydia-related products.

Some of the key players operating in the global diagnostic and therapeutic market for chlamydia infection include: Abbott Laboratories, Danaher Corporation, BioMérieux, DiaSorin SpA, NANOGEN Biopharmaceutical, Siemens AG, Thermo Fisher Scientific, Novartis Diagnostics and Fujirebio Diagnostics Inc.